

Chapter 153

Cutaneous Manifestations of Internal Malignant Disease: Cutaneous Paraneoplastic Syndromes

Christine A. DeWitt, Lucinda S. Buescher, & Stephen P. Stone

REFERENCES

1. Chung VQ et al: Clinical and pathologic findings of paraneoplastic dermatoses. *J Am Acad Dermatol* 54:745, 2006
2. Kierland RH: Acanthosis nigricans: An analysis of data in twenty-two cases and a study of its frequency in necropsy material. *J Invest Dermatol* 9:299, 1947
3. Ellis DL et al: Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons: A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. *N Engl J Med* 317:1582, 1987
4. Wilgenbus K et al: Further evidence that acanthosis nigricans maligna is linked to enhanced secretion by the tumor of transforming growth factor alpha. *Arch Dermatol Res* 284:266, 1992
5. Torley D, Bellus GA, Munro CS: Genes, growth factors and acanthosis nigricans. *Br J Dermatol* 147:1096, 2002
6. Logie A et al: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. *Hum Mol Genet* 14:1153, 2005
7. Stieler W, Plewig G: Acanthosis nigricans maligna and Leser-Trélat sign in double malignancy of the breast and stomach. *Z Hautkr* 62:344, 1987
8. Yeh JSM et al: Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: A case report and literature review. *J Am Acad Dermatol* 42:357, 2000
9. Umeda T et al: A case of long surviving gastric cancer with a malignant acanthosis nigricans. *Gan No Rinsho* 36:1042, 1990
10. Schwartz RA: Acanthosis nigricans. *J Am Acad Dermatol* 31:1, 1994
11. Cohen PR, Kurzrock R: Mucocutaneous paraneoplastic syndromes. *Semin Oncol* 24:334, 1997
12. Hodak E et al: Ichthyosiform mycosis fungoides: An atypical variant of cutaneous T-cell lymphoma. *Arch Dermatol* 50:368, 2004
13. Grimalt R et al: Pityriasis rotunda: Report of a familial occurrence and review of the literature. *J Am Acad Dermatol* 31:866, 1994
14. Aste N et al: Pityriasis rotunda: A survey of 42 cases observed in Sardinia, Italy. *Dermatology* 194:32, 1997
15. Chosidow O et al: Tripe palms associated with systemic mastocytosis: The role of transforming growth factor-alpha and efficacy of interferon-alpha. *Br J Dermatol* 138:698, 1998
16. Kleikamp S et al: Acanthosis nigricans, papillomatosis mucosae and tripe palms in a patient with metastasized gastric carcinoma. *Dtsch Med Wochenschr* 131:1209, 2006
17. Douglas F et al: Elevated levels of epidermal growth factor in a patient with tripe palms. *Br J Dermatol* 130:686, 1994
18. Krahn G et al: Receptor tyrosine kinase and p16/CDKN2 expression in a case of tripe palms associated with non-small-cell lung cancer. *Dermatology* 199:290, 1999
19. Clarke J: Malignant acanthosis nigricans. *Clin Exp Dermatol* 2:167, 1977
20. Cohen PR et al: Tripe palms and malignancy. *J Clin Oncol* 7:669, 1989
21. Walling HW et al: Improvement of acanthosis nigricans on isotretinoin and metformin. *J Drugs Dermatol* 2:677, 2003
22. Lo WL, Wong CK: Tripe palms: A significant cutaneous sign of internal malignancy. *Dermatology* 185:151, 1992
23. Lindelof B et al: Seborrheic keratoses and cancer. *J Am Acad Dermatol* 26:947, 1992
24. Grob JJ et al: The relation between seborrheic keratoses and malignant solid tumours. A case-control study. *Acta Derm Verereol* 71:166, 1991

25. Fink AM et al: Seborrheic keratoses in patients with internal malignancies: A case-control study with prospective accrual of patients. *J Eur Acad Dermatol Venereol* **23**:1316, 2009
26. Barron LA, Prendiville JS: The sign of Leser-Trélat in a young woman with osteogenic sarcoma. *J Am Acad Dermatol* **26**:344, 1992
27. Westrom DR, Berger TG: The sign of Leser-Trélat in a young man. *Arch Dermatol* **122**:1356, 1986
28. Kameya S et al: The sign of Leser-Trélat associated with carcinoma of the stomach. *Am J Gastroenterol* **83**:664, 1988
29. Ohashi N, Hidaka N: Pancreatic carcinoma associated with the Leser-Trélat sign. *Int J Pancreatol* **22**:155, 1997
30. Yamamoto T, Yokoyama A: Hereditary onset of multiple seborrheic keratoses: A variant of Leser-Trélat sign? *J Dermatol* **23**:191, 1996
31. Stone OJ: The sign of Leser-Trélat: A cutaneous sign of internal malignancy: Weakened subepithelial matrix from the effect of neoplasms on the extracellular matrix of the host. *Med Hypotheses* **40**:360, 1993
32. Pentenero M et al: Oral acanthosis nigricans, tripe palms and sign of Leser-Trélat in a patient with gastric adenocarcinoma. *Int J Dermatol* **43**:530, 2004
33. da Costa França AF et al: Acanthosis nigricans, tripe palms and the sign of Leser-Trélat in a patient with a benign hepatic neoplasia. *J Eur Acad Dermatol Venereol* **21**:846, 2007
34. Kebria MM et al: Malignant acanthosis nigricans, tripe palms and the sign of Leser-Trélat, a hint to the diagnosis of early stage ovarian cancer: A case report and review of the literature. *Gynecol Oncol* **101**:353, 2006
35. Ozturkcan S et al: The skin manifestation in patients with lung cancers. *Tuberk Toraks* **51**:23, 2003
36. Martin RW III et al: Benign Leydig cell tumor of the testis associated with human papillomavirus type 33 presenting with the sign of Leser-Trélat. *J Urol* **150**:1246, 1993
37. Inamadhar AC, Palit A: Eruptive seborrheic keratosis in human immunodeficiency virus infection: A coincidence of 'the sign of Leser-Trélat'? *Br J Dermatol* **149**:435, 2003
38. Flugman SL et al: Transient eruptive seborrheic keratoses associated with erythrodermic psoriasis and erythrodermic drug eruption: Report of two cases. *J Am Acad Dermatol* **45**:S212, 2001
39. Patton T et al: Inflammation of seborrheic keratoses caused by cytarabine: A pseudo sign of Leser-Trélat. *J Drugs Dermatol* **3**:565, 2004
40. Holdiness MR: The sign of Leser-Trélat. *Int J Dermatol* **25**:564, 1986
41. Tanaka T et al: A case of bullous pemphigoid and transitional cell carcinoma of the bladder. *Arch Dermatol* **1983**;119:704-5
42. Soderdahl G et al: Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines. *Int J Cancer* **41**(4):636-641, 1988
43. Iihara K et al: Growth-regulatory mechanism of two human esophageal-cancer cell lines in protein-free conditions. *Int J Cancer* **55**(3):364-370
44. Spellman JE Jr et al: Clonal interactions in a human squamous cell carcinoma. *J Surg Res* **58**(2):165-174, 1995
45. Bolognia JL, Brewer YP, Cooper DL: Bazex syndrome (acrokeratosis paraneoplastica) an analytic review. *Medicine* **70**(4):269-280, 1991
46. Strobel E, Bouveret C, Kohl P: Acrokeratosis paraneoplastica of Bazex as an indicator for underlying squamous cell carcinoma of the lung. *J Cancer Res Clin Oncol* **132**:376-378, 2006
47. Gill D, Fergin P, Kelly J: Bullous lesions in Bazex syndrome and successful treatment with oral psoralen phototherapy. *Australas J Dermatol* **42**:278-280, 2001
48. Basset-Sequin N et al: Prognostic factors and predictive signs of malignancy in adult dermatomyositis. *Arch Dermatol* **126**:633, 1990
49. Hill C et al: Frequency of specific cancer types in dermatomyositis and polymyositis: A population study. *Lancet* **357**:96, 2001
50. Zantos D et al: The overall and temporal association of cancer with polymyositis and dermatomyositis. *J Rheumatol* **21**:1855, 1994
51. Sakauchi F et al: The association of systemic sclerosis with malignancy neoplasms. *Nihon Rinsho Meneki Gakkai Kaishi* **27**:402, 2004
52. Chatterjee S: Risk of malignancy in scleroderma: A population-based cohort study. *Arthritis Rheum* **52**:2415, 2005
53. Derk CT et al: Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: A nested case-control study. *Clin Rheumatol* **25**:1, 2006
54. Derk CT et al: A cohort study of cancer incidence in systemic sclerosis. *J Rheumatol* **33**:1113, 2006

55. Derk CT et al: Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. *J Rheumatol* **32**:637, 2005
56. Eubanks LE, McBurney E, Reed R: Erythema gyratum repens. *Am J Med Sci* **321**(5):302-305, 2001
57. Moore HJ: Does the pattern of erythema gyratum repens depend on a reaction-diffusion system? *Br J Dermatol* **197**:723, 1982
58. Stone OJ: A mechanism of peripheral spread or localization of inflammatory reactions. Role of the localized ground substance adaptive phenomenon. *Med Hypotheses* **29**:167-169, 1989
59. Skolnick M, Mainman ER: Erythema gyratum repens with metastatic adenocarcinoma. *Arch Dermatol* **111**:227-229, 1975
60. Appell ML, Ward WQ, Tyring SK: Erythema gyratum repens. A cutaneous marker of malignancy. *Cancer* **62**:548-550, 1988
61. Langlois JC, Shaw JM, Odland GF: Erythema gyratum repens unassociated with internal malignancy. *J Am Acad Dermatol* **12**:911-913, 1985
62. Graham-Brown RA: Bullous pemphigoid with figurate erythema associated with carcinoma of the bronchus. *Br J Dermatol* **117**:385-388, 1987
63. Shupak JL, Berczeller PH, Stevens DM: The glucagonoma syndrome. *J Dermatol Surg Oncol* **4**:242-247, 1978
64. Klein S et al: In vivo assessment of the metabolic alterations in glucagonoma syndrome. *Metab Clin Exp* **41**:1171-1175, 1992
65. Kindmark H et al: Endocrine pancreatic tumors with glucagon hypersecretion: A retrospective study of 23 cases during 20 years. *Med Oncol* **24**:330, 2007
66. Magro C, Crowson N, Mihm M: Cutaneous manifestations of nutritional deficiency states and gastrointestinal disease. In: *Lever's Histopathology of the Skin*, edited by D Elder et al. Philadelphia, Lippincott-Raven Publishers, 1997, p. 355
67. Holmes A et al: Reversal of a neurologic paraneoplastic syndrome with octreotide (sandostatin) in a patient with glucagonoma. *Am J Med* **91**:434-436, 1991
68. Boden G: Insulinoma and glucagonoma. *Semin Oncol* **14**:253-262, 1987
69. Schmid R et al: Effect of somatostatin on skin lesions and concentrations of plasma amino acids in a patient with glucagonoma syndrome. *Hepatogastroenterology* **35**:34-37, 1988
70. Fitzgerald RL et al: Sweet's syndrome. *Int J Dermatol* **35**:9, 1996
71. Cohen PR, Kurzrock R: Sweet's syndrome and cancer. *Clin Dermatol* **11**:14, 1993
72. Cohen PR et al: Sweet's syndrome in patients with solid tumors. *Cancer* **72**:2723, 1993
73. Bennett ML et al: Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. *Medicine* **79**:37, 2000
74. Setterfield JF et al: Pyoderma gangrenosum associated with severe oropharyngeal involvement and IgA paraproteinemia. *Br J Dermatol* **144**:393, 2001
75. Blade J, Rosinol L: Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. *Curr Treat Options Oncol* **7**:237, 2006
76. Mehregan DA, Winkelmann RK: Necrobiotic xanthogranuloma. *Arch Dermatol* **128**:94, 1992
77. Pomann JJ, Rudner EJ: Scleromyxedema revisited. *Int J Dermatol* **42**:31, 2003
78. Iwahashi N et al: Massive hemorrhage and pseudo-obstruction of the small intestine caused by primary AL amyloidosis associated with gastric cancer: Report of a case. *Surg Today* **34**:871, 2004
79. White JD et al: Primary amyloidosis of the breast associated with invasive breast cancer. *Oncol Rep* **11**:761, 2004
80. Gagel RF et al: Multiple endocrine neoplasia type 2A associated with cutaneous lichen amyloidosis. *Ann Intern Med* **111**:802, 1989
81. Swerdlow AJ et al: Mortality and cancer incidence in patients with dermatitis herpetiformis: A cohort study. *Br J Dermatol* **129**:140, 1993
82. Hervonen K et al: Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives. *Br J Dermatol* **152**:82, 2005
83. Collin P, Pukkala E, Reunala T: Malignancy and survival in dermatitis herpetiformis: A comparison with celiac disease. *Gut* **38**:528, 1996
84. Askling J et al: Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. *Gastroenterology* **123**:1726, 2002
85. Sigurgeirsson B, Agnarsson BA, Lindelöf B: Risk of lymphoma in patients with dermatitis herpetiformis. *Br Med J* **308**:13, 1994
86. Wojnarowska F et al: Guidelines for the management of bullous pemphigoid. *Br J Dermatol* **147**:214, 2002
87. Ogawa H et al: The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. *J Dermatol Sci* **9**:136, 1995

88. Bourdon-Lanoy E et al: Bullous pemphigoid in young patients: A retrospective study of 74 cases. *Ann Dermatol Venereol* **132**:115, 2005
89. Fretzin DF: Malignant down. *Arch Dermatol* **95**:294-297, 1967
90. Jemec GBE: Hypertrichosis lanuginosa acquisita. Report of a case and review of the literature. *Arch Dermatol* **122**:805-808, 1986
91. Hovenden AL: Hypertrichosis lanuginosa acquisita associated with malignancy. *Clin Dermatol* **11**:99-106, 1993
92. Van der Lugt L, Dudok de Wit C: Hypertrichosis lanuginosa acquisita. *Dermatologica* **146**:46-54, 1973
93. Casanova JM, Puig T, Rubio M: Hypertrichosis of the eyelashes in acquired immunodeficiency syndrome. *Arch Dermatol* **123**:1599-1601, 1987
94. Walsh-McMonagle D, Green D: Low-molecular-weight heparin in the management of Trousseau's syndrome. *Cancer* **80**:649, 1997
95. Ogren M et al: Trousseau's syndrome- what is the evidence? A population-based autopsy study. *Thromb Haemost* **95**:541, 2006
96. Caccaccio C: The MET oncogene drives a genetic programme linking cancer to haemostasis. *Nature* **434**:396, 2005
97. Morita S et al: High affinity binding of heparin by necrotic tumour cells neutralizes anticoagulant activity- implications for cancer related thromboembolism and heparin therapy. *Thromb Haemost* **86**:616, 2001
98. Tsao H: Update on familial cancer syndromes and the skin. *J Am Acad Dermatol* **42**:939, 2000
99. Zbar B et al: Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. *Cancer Epidemiol Biomarkers Prev* **11**:393, 2002
100. Brandi ML: Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* **87**:2994, 2002
101. Ilhan M et al: Palmoplantar keratoderma is associated with esophagus squamous cell cancer in Van region of Turkey: A case control study. *BMC Cancer* **5**:90, 2005
102. Toro JR et al: Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. *Am J Hum Genet* **73**:95, 2003
103. Spitz JL: *Genodermatoses: A Clinical Guide to Genetic Skin Disorders*, 2nd edition, edited by Joel L. Spitz. Philadelphia, Lippincott Williams & Wilkins, 2005
104. Alter BP: Cancer in Fanconi anemia, 1927-2001. *Cancer* **97**:425, 2003
105. Krathen RA, Orengo IF, Rosen T: Cutaneous metastasis: A meta-analysis of data. *South Med J* **96**:164, 2003
106. Saeed S, Keehn CA, Morgan MB: Cutaneous metastasis: A clinical, pathological, and immunohistochemical appraisal. *J Cutan Pathol* **31**:419-430, 2004
107. Stratakis CA, Kirschner LS, Carney JA: Clinical and molecular features of the Carney complex: Diagnostic criteria and recommendations for patient evaluation. *J Clin Endocrinol Metab* **86**:4041, 2001